1. INTRODUCTION AND DEFINITION
- Definition: A heterogeneous group of >50 inherited metabolic disorders characterized by the accumulation of macromolecules (lipids, glycoproteins, mucopolysaccharides) within lysosomes due to specific enzyme, transporter, or activator protein defects.
- Pathophysiology:
- “Garbage Disposal” Failure: Lysosomes fail to degrade substrates.
- Storage: Substrates accumulate, causing lysosomal hypertrophy and cellular dysfunction.
- Consequences: Disrupted autophagy, mitochondrial dysfunction, inflammation, and apoptosis leading to multi-organ damage.
- Epidemiology: Combined incidence ~1 in 5,000 live births.
- Inheritance:
- Most are Autosomal Recessive.
- X-Linked Recessive: Hunter Syndrome (MPS II), Fabry Disease, Danon Disease.
2. CLASSIFICATION (BASED ON ACCUMULATED SUBSTRATE)
| Group | Examples | Accumulated Substrate | Key Features |
|---|---|---|---|
| Sphingolipidoses | Gaucher, Niemann-Pick, Tay-Sachs, Fabry, Krabbe, MLD | Sphingolipids, Gangliosides | CNS regression, Organomegaly, Cherry-red spot. |
| Mucopolysaccharidoses (MPS) | Hurler (I), Hunter (II), Sanfilippo (III), Morquio (IV) | Glycosaminoglycans (GAGs) | Coarse facies, Dysostosis multiplex, Organomegaly. |
| Mucolipidoses (ML) | I-Cell Disease (ML II), ML III | Oligosaccharides, Lipids | MPS-like features but normal urine GAGs. |
| Glycogen Storage (Lysosomal) | Pompe Disease (GSD II) | Glycogen | Cardiomegaly, Hypotonia (No hypoglycemia). |
| Oligosaccharidoses | Mannosidosis, Fucosidosis | Oligosaccharides | Coarse facies, vacuoles in lymphocytes. |
| Neuronal Ceroid Lipofuscinoses | NCL (Batten Disease) | Lipopigments | Seizures, Dementia, Vision loss. |
| Lipid Transport Defects | Niemann-Pick C | Cholesterol | Ataxia, Vertical Gaze Palsy. |
3. CLINICAL APPROACH AND PRESENTATION
Presentation varies by age of onset and severity.
A. Phenotypic Patterns
- Dysmorphic / Somatic Pattern (MPS-like):
- Coarse facies, macroglossia, stiff joints, hepatosplenomegaly.
- Examples: MPS, Mucolipidoses, Mannosidosis, Sialidosis.
- Neurologic / Neurodegenerative Pattern:
- Progressive regression, seizures, ataxia, spasticity.
- Examples: Tay-Sachs, Krabbe, Metachromatic Leukodystrophy (MLD), Sanfilippo (MPS III).
- Visceral / Organomegaly Pattern:
- Hepatosplenomegaly without marked dysmorphism.
- Examples: Gaucher (Type 1), Niemann-Pick B, Wolman disease.
B. “Clinical Clues” (Buzzwords)
- Cherry-Red Spot: Tay-Sachs, Sandhoff, Niemann-Pick A, Sialidosis, Farber.
- Corneal Clouding: MPS I (Hurler), MPS VI (Maroteaux-Lamy), GM1 Gangliosidosis. (Clear in Hunter & Sanfilippo).
- Angiokeratomas: Fabry Disease, Fucosidosis, Sialidosis.
- Dysostosis Multiplex: MPS, Mucolipidoses.
- Gibbus Deformity: MPS I (Hurler), MPS IV (Morquio).
- Acroparesthesia (Pain): Fabry Disease.
- Hydrops Fetalis: MPS VII (Sly), Gaucher (severe), Sialidosis, Niemann-Pick C.
4. DIAGNOSTIC EVALUATION
Step 1: Screening Tests
- Urine:
- GAGs (Dermatan/Heparan Sulfate): Positive in MPS.
- Oligosaccharides: Positive in Mannosidosis, Fucosidosis, Pompe.
- Blood Smear:
- Vacuolated Lymphocytes: Pompe, Niemann-Pick A, Batten disease, Mannosidosis.
- Radiology (Skeletal Survey):
- Look for Dysostosis Multiplex (Ovoid vertebrae, spatulate ribs, proximal pointing metacarpals).
Step 2: Confirmatory Testing (Gold Standard)
- Enzyme Assay:
- Measured in leukocytes, plasma, or dried blood spots (DBS).
- Demonstration of deficient activity (<5-10%) of the specific lysosomal enzyme.
- Example: Beta-glucosidase deficiency = Gaucher; Hexosaminidase A = Tay-Sachs.
- Biomarkers (Monitoring):
- Chitotriosidase: Markedly elevated in Gaucher and Niemann-Pick.
- Lyso-Gb1 / Lyso-SM-509: Sensitive for Gaucher/Niemann-Pick.
Step 3: Molecular Genetics
- Next-Generation Sequencing (NGS):
- Single gene (if diagnosis clear).
- LSD Gene Panels: Preferred for overlapping phenotypes.
- Whole Exome Sequencing (WES) for difficult cases.
5. SPECIFIC IMPORTANT DISORDERS (SUMMARY)
A. Gaucher Disease (Most Common LSD)
- Defect: Acid Beta-Glucosidase (GBA).
- Features: Hepatosplenomegaly, Pancytopenia, Bone pain (Erlenmeyer flask deformity).
- Types: Type 1 (Non-neuronopathic), Type 2 (Acute infantile), Type 3 (Chronic neuronopathic).
- Tx: ERT + SRT.
B. Niemann-Pick Disease
- Type A/B (ASMD): Acid Sphingomyelinase deficiency. HSM, Cherry-red spot (A), Lung disease (B).
- Type C: Cholesterol trafficking defect. Ataxia, Vertical Supranuclear Gaze Palsy (VSGP).
C. Pompe Disease (GSD II)
- Defect: Acid Alpha-Glucosidase (GAA).
- Features: Approach to a floppy infant, Macroglossia, Massive Cardiomegaly (Infantile); Limb-girdle weakness (Late-onset).
- Tx: ERT.
D. Tay-Sachs Disease (GM2 Gangliosidosis)
- Defect: Hexosaminidase A (HEXA).
- Features: Hyperacusis (startle), Cherry-red spot, Macrocephaly, Neurodegeneration. NO organomegaly.
E. Fabry Disease
- Defect: Alpha-Galactosidase A (GLA). X-Linked.
- Features: Acroparesthesia (burning pain), Angiokeratomas, Hypohidrosis, Renal failure, Stroke.
- Tx: ERT + Chaperone.
F. Metachromatic Leukodystrophy (MLD)
- Defect: Arylsulfatase A.
- Features: Gait disturbance, spasticity, regression, gallbladder accumulation. MRI: “Tigroid” pattern of demyelination.
6. MANAGEMENT
Moving from supportive care to disease-modifying therapies.
A. Enzyme Replacement Therapy (ERT)
Recombinant enzymes given IV (weekly/biweekly). Effective for visceral symptoms; generally does not cross Blood-Brain Barrier (BBB).
- Gaucher: Imiglucerase, Velaglucerase.
- Fabry: Agalsidase alfa/beta.
- Pompe: Alglucosidase alfa.
- MPS I: Laronidase.
- MPS II: Idursulfase.
- MPS IV: Elosulfase alfa.
- MPS VI: Galsulfase.
- Acid Sphingomyelinase Deficiency (Niemann-Pick B): Olipudase alfa.
- Batten Disease (CLN2): Cerliponase alfa (Intraventricular).
B. Substrate Reduction Therapy (SRT)
Oral small molecules that inhibit substrate synthesis.
- Gaucher: Eliglustat, Miglustat.
- Niemann-Pick C: Miglustat (stabilizes neurological progression).
C. Chaperone Therapy
Small molecules that stabilize misfolded enzymes (amenable mutations only).
- Fabry: Migalastat.
D. Hematopoietic Stem Cell Transplantation (HSCT)
- Donor cells provide enzyme source.
- Standard of Care: MPS I (Hurler) if <2 years (preserves cognition).
- Effective: X-linked Adrenoleukodystrophy (early cerebral).
- Variable/Ineffective: Sanfilippo, Hunter, severe Gaucher.
E. Supportive Care
- Physical therapy for contractures.
- VP shunt for hydrocephalus.
- Management of seizures and feeding.
7. PROGNOSIS
- Untreated: Most infantile forms are fatal in the first decade due to neurodegeneration or cardiorespiratory failure.
- Treated: Life expectancy significantly improved with ERT/HSCT (e.g., Gaucher Type 1 patients live near-normal lives).
- Key determinant: Presence and severity of Central Nervous System involvement (hardest to treat).